The Optimize 2013: Antibody Engineering & Discovery Conference
25 Feb. 2013 to 27 Feb. 2013
Maritim Hotel Frankfurt, Theodor-Heuss-Allee , Frankfurt, Germany
With many antibody companies facing shared challenges in discovery and engineering, innovative strategies are emerging to improve existing protocols and drive revolution in the field. This meeting is focusing on the early stages of antibody development and discussing with peer companies, such as Abbott, Amgen, Pfizer, MedImmune, GSK, Janssen and Novartis. In the meeting, companies will have communication on each other’s solutions and experiences to help redesign the discovery and engineering practices to create antibody candidates with blockbuster potential.
1. Redesign antibody discovery strategies by identifying alternative routes to unique epitope discovery with insights on the latest from Pfizer, Baxter andMedImmune;
2. Reduce attrition later in development by developing manufacturability assessments of promising molecules early on in discovery with case study examples from Novartis and Bayer;
4. Find out how Amgen are developing a half-life extension platform within their biologics discovery department to improve own practices and exceed industry standards;
5.Exploit bispecific formats and antibody domains as effective therapeutics for indications with preclinical and clinical data from TRION and GSK.
Antibody, protein, biologics, engineering, discovery, lead, optimisation, technology, development, R&D, epitope